Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolit

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., A

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass.,

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Co

Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The tra

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi

– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis unde

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Over

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, init

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha

Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades

HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) fro

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

Karyopharm stock plunged after hours after its Phase 3 endometrial cancer trial missed the primary e

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

A trend favoring the selinexor arm was observed in the modified intent to treat (mITT) population (n

– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Comp

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Eng

– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favorin

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove